Syntaxin appoints Executive Chairman

01-Oct-2009 - United Kingdom

Syntaxin, a biopharmaceutical company developing novel biologic drugs that control cell secretion, reports that Andrew Sandham has been appointed Executive Chairman. This follows the resignation of CEO, Patrick Doyle, for personal reasons. Mr Sandham has worked closely with Syntaxin since its formation in 2005, as chairman of the board. A search has been initiated for the vacant position of CEO.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances